weekly_roundup
BioTechSign Daily Catalyst Roundup - November 17, 2026
Top BioTechSign catalyst names today: EYPT, MLTX, VBIO, NKTR, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 17, 2026
Daily Biotech Catalyst Digest: November 17, 2026
EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| MLTX | MoonLake Immunotherapeutics | 82.2 | A | clinical activity 100%, short interest 70%, publication signal 35% |
| VBIO | Valion Bio, Inc. | 75.5 | B | dilution risk 100%, short interest 10% |
| NKTR | Nektar Therapeutics | 74.4 | B | publication signal 100%, short interest 90%, clinical activity 75% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| BBIO | BridgeBio Pharma | 73.2 | B | PDUFA timing 100%, publication signal 100%, clinical activity 100% |
Recent Grade-Change Queue
- INBX (Inhibrx Inc) currently grades C with a 55.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 83%.
- PASG (Passage Bio) currently grades F with a 13.3/100 catalyst score. Main inputs: publication signal 65%, dilution risk 53%, short interest 10%.
- INO (Inovio Pharmaceuticals, Inc.) currently grades D with a 40.9/100 catalyst score. Main inputs: publication signal 100%, dilution risk 89%, short interest 70%.
- SMMT (Summit Therapeutics Inc.) currently grades C with a 54.6/100 catalyst score. Main inputs: publication signal 100%, clinical activity 92%, short interest 90%.
- NCEL (NewcelX Ltd.) currently grades D with a 46.0/100 catalyst score. Main inputs: dilution risk 62%, short interest 10%, publication signal 5%.
- KURA (Kura Oncology, Inc.) currently grades D with a 39.4/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 65%.
- ARGX (argenx SE) currently grades F with a 17.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 15%, short interest 10%.
- VBIO (Valion Bio, Inc.) currently grades B with a 75.5/100 catalyst score. Main inputs: dilution risk 100%, short interest 10%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.